Organon & Co. (OGN) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals several negative factors: declining revenue guidance, margin compression, and a net loss in Q4 2025. Despite growth in biosimilars and cost savings, these are overshadowed by underperformance in key areas like women's health and respiratory portfolio. Additionally, management's vague responses in the Q&A section, especially regarding the Audit Committee investigation, add uncertainty. The slight positive from biosimilars and cost savings isn't enough to outweigh these negatives, leading to an overall negative sentiment, likely resulting in a -2% to -8% stock price decline.
Key Financial Performance
Revenue Organon delivered $6.2 billion in revenue in 2025, down 3% year-over-year on both a reported and ex-exchange basis. The decline was attributed to the loss of exclusivity (LOE) of Atozet, policy-related changes in the U.S. for Nexplanon, and revised medical guidelines deprioritizing montelukast in certain international markets.
Adjusted EBITDA Adjusted EBITDA was $1.9 billion in 2025, consistent with the prior year. Despite a 150 basis point gross margin degradation, the company achieved over $200 million in cost savings, which offset investments in growth drivers like Vtama.
Women's Health Revenue Women's health revenue was down 16% ex-FX in Q4 2025 and down 2% for the full year. Nexplanon sales decreased 20% ex-FX in Q4 and 4% for the full year due to U.S. policy-related access restrictions, changes in purchasing practices by smaller clinics, and a transition to a 5-year label. However, strong ex-U.S. growth, particularly in Latin America, partially offset these declines.
Fertility Business Revenue The fertility business declined 6% ex-FX in Q4 2025 but grew 8% for the full year. Growth was driven by U.S. performance in the first half of 2025 and geographic expansion, which offset declines in China due to socioeconomic trends.
Biosimilars Revenue Biosimilars revenue grew, driven by Hadlima, which increased 61% ex-FX globally in 2025. Growth was attributed to its strong clinical profile, effective pricing strategy, and expansion into Canada and Puerto Rico. New launches like denosumab biosimilars and Tofidence also contributed.
Established Brands Revenue Established brands revenue declined 5% ex-FX in Q4 2025 and for the full year. The decline was primarily due to the LOE of Atozet, which was a 400 basis point headwind. However, contributions from Vtama and Emgality helped offset some of the pressure.
Gross Margin Non-GAAP adjusted gross margin was 60.1% for full year 2025, down from 61.6% in 2024. The decline was driven by pricing pressure and unfavorable product mix.
Adjusted EBITDA Margin Adjusted EBITDA margin was 30.7% for full year 2025, consistent with 2024. The decline in gross margin was offset by lower R&D expenses.
Net Income Net loss for Q4 2025 was $205 million, compared to net income of $109 million in Q4 2024. The loss included a non-cash goodwill impairment of $301 million related to stock price decline and underperformance in the U.S.
Free Cash Flow Free cash flow for full year 2025 was $960 million, consistent with the prior year. Onetime costs related to restructuring and manufacturing separation activities were $270 million.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Hadlima: Performed better than expected, driven by solid performance and contributions from new launches.
Vtama: Delivered $128 million of global revenue in 2025.
Emgality: Showed strong growth in 2025.
Nexplanon: FDA approved sNDA to extend duration from 3 to 5 years, potentially broadening the addressable market.
Denosumab biosimilars: Approved by FDA in August and launched in the U.S. in late September.
Latin America: Improved access for Nexplanon, contributing to strong ex-U.S. growth.
China: Fertility business faced challenges due to socioeconomic trends, despite holding market share.
Canada and Puerto Rico: Expansion of Hadlima into these regions.
Cost savings: Achieved over $200 million in cost savings in 2025 through significant efforts.
Debt reduction: Lowered dividend payout ratio and divested Jada system, resulting in $390 million in net proceeds for debt reduction.
Adjusted EBITDA: Maintained margins at $1.9 billion despite gross margin degradation.
Divestiture of Jada system: Generated $390 million in net proceeds to reduce net debt and improve balance sheet capacity.
Clinical program discontinuation: Discontinued early-stage clinical programs to focus on products already in the market.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Revenue was down 3% in 2025, with continued headwinds from loss of exclusivity (LOE) for key products like Atozet and pricing pressures in various portfolios.
Nexplanon Challenges: Nexplanon faced policy-related access restrictions in the U.S., impacting its leading market share among long-acting reversible contraceptives (LARCs). Additionally, smaller independent clinics are switching to specialty pharmacy claims, and there is a volume headwind from transitioning to a 5-year label.
Fertility Business Decline: The fertility business faced declines in China due to socioeconomic trends and is expected to face increased competition in the U.S. in 2026 due to a competitor's agreement with the administration's new Direct Access Program.
Jada System Divestiture: The divestiture of the Jada system will result in a revenue headwind of about 120 basis points in 2026.
Pricing Pressures: Pricing pressures were significant in 2025, particularly in the respiratory portfolio, biosimilars, and fertility segments. This trend is expected to continue in 2026, albeit at a slightly reduced rate.
Gross Margin Decline: Gross margin declined in 2025 due to pricing pressures and unfavorable product mix. A further decline of 75 to 100 basis points is expected in 2026, driven by higher cost of goods sold.
Debt and Leverage: Net leverage remains high at 4.3x, though efforts are being made to reduce it below 4x by the end of 2026. High interest expenses of approximately $500 million are expected to persist.
Regulatory and Policy Risks: Government policy-related changes in the U.S. and revisions to medical guidelines in international markets have negatively impacted key products like Nexplanon and Singulair.
Competitive Pressures: Increased competition in the fertility and biosimilar markets is expected to create headwinds in 2026, particularly in the U.S.
Supply Chain and Manufacturing Costs: Higher costs associated with manufacturing separation activities and inventory buildup in established brands and biosimilars are expected to impact free cash flow in 2026.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue and Adjusted EBITDA Projections for 2026: Organon expects to deliver approximately $6.2 billion in revenue and $1.9 billion in adjusted EBITDA for 2026. Revenue is anticipated to remain flat compared to 2025 on a constant currency basis, pro forma for the Jada system divestiture. Adjusted EBITDA is expected to be managed to about $1.9 billion despite anticipated gross margin deterioration of 75 to 100 basis points.
Biosimilars Growth: Biosimilars are expected to deliver flat to modest growth in 2026. Growth will be driven by Hadlima and contributions from new assets, offsetting declines in Ontruzan and Renflexis. Future launches include a pertuzumab biosimilar asset in UCAN in 2027 and in the U.S. in 2028.
Women's Health Segment: Nexplanon is expected to face continued headwinds in the U.S. due to policy-related access restrictions, changes in purchasing practices, and a transition to a 5-year label. However, strong growth is anticipated outside the U.S., particularly in Latin America. The fertility business is expected to face challenges in 2026 due to increased competition in the U.S. and socioeconomic trends in China.
Established Brands Performance: Established brands are expected to return to flat performance in 2026, with contributions from Vtama and Emgality offsetting continued pressure in the respiratory franchise.
Free Cash Flow and Capital Expenditures: Free cash flow in 2026 is expected to resemble levels from 2024 and 2025, with costs associated with manufacturing separation activities estimated at about $100 million. Capital expenditures are expected to increase, driven by these activities and inventory growth in established brands and biosimilars.
Debt Reduction and Leverage: Organon aims to achieve net leverage below 4x by the end of 2026, supported by approximately $390 million in net proceeds from the Jada divestiture and disciplined capital deployment.
Gross Margin and Operating Expenses: Adjusted gross margin is expected to decline by 75 to 100 basis points in 2026 due to higher cost of goods sold. SG&A expenses are projected to remain in the mid-20% range of sales, and R&D spending is expected to be in the mid-single-digit range.
Tax Rate and Interest Expense: The non-GAAP tax rate for 2026 is estimated to be between 27.5% and 29.5%, reflecting the impact of OECD's Pillar 2 global minimum tax and other factors. Interest expense is projected to remain at approximately $500 million.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Dividend Payout Ratio: The company decided to lower its dividend payout ratio in 2025.
Debt Reduction: Excess funds from the reduced dividend payout ratio were applied to debt reduction.
Share Repurchase: The company retired approximately $530 million of debt, including $419 million of Organon's 5.125% notes due in 2031.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why was the Audit Committee investigation limited to Nexplanon, and how can we know a comprehensive review has been taken?
A:Carrie Cox stated, 'I'm sorry. We can't provide any additional color at this point.'
Q:What is the status of the FDA's draft guidance on biosimilars, and what impact will it have on Organon's business?
A:Joseph Morrissey explained that the impact would be incremental. Organon is focusing on partnerships and expanding biosimilars like Hadlima and denosumab in the U.S. and other markets.
Q:Can you provide details on Nexplanon's contribution to 2026 sales guidance and the impact of the longer-acting implant?
A:Matthew Walsh stated that Nexplanon sales are expected to remain flat year-on-year. Growth is anticipated outside the U.S., while U.S. sales may dip due to reduced reinsertion rates with the 5-year label. Long-term growth is expected due to the product's attractiveness.
Q:How is the $275 million in annualized cost savings being utilized, and what is the impact on EBITDA?
A:Matthew Walsh explained that the savings are being reinvested into growth opportunities like Vtama promotions. Additional OpEx savings are planned for 2026 to address gross margin compression.
Q:Does the 2026 Nexplanon outlook account for volume bottlenecks or certification friction due to the REMS program?
A:Juan Camilo Ferreira expressed confidence in maintaining volume through retraining prescribers, which will require minimal effort for recertification.
Q:What are the latest thoughts on operating costs and margins over time, and how long will the 5-year Nexplanon headwind last?
A:Matthew Walsh emphasized the need for efficiency and balancing OpEx with revenue growth. The 5-year headwind is expected to be most pronounced in 2026 and diminish significantly by 2027.
Q:What is the outlook for established brands and competitive dynamics for Vtama?
A:Joseph Morrissey noted that established brands will face challenges but remain stable overall. Matthew Walsh stated that Vtama is expected to grow 20%-25% year-on-year, competing well with other nonsteroidal topicals.
Q:What is the update on the search for a permanent CEO?
A:Carrie Cox mentioned that a robust process is underway, but there is no public update to share.
Q:What is the go-to-market strategy for the denosumab biosimilar in the osteoporosis setting?
A:Matthew Walsh stated that the product will face competitive markets, with peak revenues estimated at $100 million over five years.
Q:Review of Unclear Management Responses
A:Management avoided providing a direct answer to the question about the Audit Committee investigation's scope and whether a comprehensive review has been taken, citing an inability to provide additional color.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
China
Hadlima
Jada system
LOE
Non
Slide
VBP
Vtama Emgality
activity
basis point
benefit
biosimilars
brand
cash flow
change
contribution
debt
decline margin
divestiture
driver
ex FX
fertility
headwind
income share
item
loss
margin decline
measure
portfolio
pressure
price
pricing
program
statement
tax
volume
woman
year
OGN Transcript
Organon & Co. (OGN) Q4 2025 Earnings Call Transcript
Unknown2-12
The earnings call reveals several negative factors: declining revenue guidance, margin compression, and a net loss in Q4 2025. Despite growth in biosimilars and cost savings, these are overshadowed by underperformance in key areas like women's health and respiratory portfolio. Additionally, management's vague responses in the Q&A section, especially regarding the Audit Committee investigation, add uncertainty. The slight positive from biosimilars and cost savings isn't enough to outweigh these negatives, leading to an overall negative sentiment, likely resulting in a -2% to -8% stock price decline.
Organon & Co. (OGN) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Neutral12-3
Organon & Co. (OGN) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call summary shows mixed signals: positive revenue guidance and debt reduction are offset by challenges in the respiratory segment and flat growth for Nexplanon. The Q&A highlights management's cautious outlook, especially regarding the CEO search and competitive pressures. Despite some positive developments, such as Vtama's growth potential, uncertainties around established brands and leadership changes create a balanced sentiment. Without market cap data, the overall prediction is neutral, reflecting both opportunities and risks.
Organon & Co. (OGN) Q2 2025 Earnings Call Transcript
Positive8-5
The earnings call shows strong financial performance with significant revenue growth in key products like Hadlima and Vtama. Despite slight margin declines, positive developments in market expansion and strategic investments, such as in DTC and telehealth campaigns, are promising. The Q&A highlights confidence in overcoming challenges, with plans for growth and deleveraging. No negative guidance or major concerns were raised, and the optimistic outlook on product expansions and sales strategies suggests a likely positive stock price reaction in the short term.
OGN Slides
OGN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
